News
Media
Conferences
Publications
Events
CME/CE
Resources
Career Center
Subscribe

Your AI-Trained Oncology Knowledge Connection!

|Articles|August 22, 2010

practiceguidelines image

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Related Content

Data from the phase 3b ALIDHE study may enrich knowledge on ivosidenib plus azacitidine’s safety and efficacy in IDH1-mutated acute myeloid leukemia.

Ivosidenib Combo Shows Preliminary Activity in IDH1-Mutated AML

December 29th 2025

Janjigian Provides Perspective on Durvalumab Combo Approval in Gastric/GEJ Cancer

ByAriana Pelosci

December 29th 2025

Rahul Banerjee, MD, FACP, and Brooke Adams, PharmD, BCOP, discussed the top hematologic oncology abstracts from the 2025 ASH Annual Meeting and Exposition.

What’s New in Hematology/Oncology? Discussing the 2025 ASH Annual Meeting

ByRahul Banerjee, MD, FACP,Brooke Adams, PharmD, BCOP

December 29th 2025

The addition of zovegalisib to fulvestrant led to rapid declines in PIK3CA and ESR1 ctDNA in the HR-positive/HER2-negative advanced breast cancer group.

Zovegalisib Combo Confers Efficacy Benefit in PIK3CA-Mutated Breast Cancer

ByRoman Fabbricatore

December 28th 2025

‘Relatively Low’ AEs Noted With Durvalumab/FLOT in Gastric/GEJ Cancer

ByYelena Y. Janjigian, MD

December 28th 2025

Trending on CancerNetwork

Spotlighting the Top 10 FDA Oncology Approvals in 2025

A Look Back on the Top 10 Oncology Interviews in 2025

Zovegalisib Combo Confers Efficacy Benefit in PIK3CA-Mutated Breast Cancer

‘Relatively Low’ AEs Noted With Durvalumab/FLOT in Gastric/GEJ Cancer

Durvalumab/FLOT Cemented as New SOC in Gastric/GEJ Cancers